Acasti Pharma: Plunges after blood disorder drug fails to meet main goal in study

Grace Therapeutics

31/08/2020 13:58

** Drug developer's shares  ACST.V  plunge ~60% to 28 cents
premarket
    ** Stock 2nd-most heavily traded across U.S. indexes and
biggest pct loser
    ** Late-stage trial of drug candidate, CaPre, to treat
hypertriglyceridemia failed to meet the main goal - ACST
 urn:newsml:reuters.com:*:nGNX4FfbJk
    ** An unusual reduction in triglyceride levels in the
placebo group meant that statistical significance was not
achieved, says ACST
    ** Co says will not file a marketing application with the
FDA and does not plan to conduct additional clinical trials for
CaPre    
    ** Stock down ~71% in value YTD

 (Reporting by Trisha Roy in Bengaluru)
 ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6182 3635;))